| 452 | In combination with a 5HT3 receptor antagonist and dexamethasone for highly emetogenic chemotherapy (HEC) regimens:
- Cisplatin-based chemotherapy where a single daily dose is greater than or equal to 70 mg per meter squared
- Cisplatin and cyclophosphamide combinations where the single daily dose is greater than or equal to 50mg per meter squared
- Cisplatin (any dose) given for 3 to 5 consecutive days
- Non-cisplatin based highly emetogenic chemotherapy (such as those containing anthracycline greater than or equal to 60mg per meter squared plus cyclophosphamide)
Dosage: Recommend aprepitant 125mg orally on Day 1 of HEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle.
|
| | LU Authorization Period: 1 year |
| 453 | For patients receiving moderately emetogenic chemotherapy (MEC) regimens AND who have had inadequate symptom control using a 5HT3 antagonist and dexamethasone in a previous cycle.
Dosage: Recommend aprepitant 125mg orally on Day 1 of MEC followed by 80mg orally on Days 2 to 3 post-chemotherapy for each cycle. |
| | LU Authorization Period: 1 year |
